Assessing the impact of elexacaftor/tezacaftor/ivacaftor on work productivity and activity impairment in people living with cystic fibrosis in Canada. (PubMed, J Cyst Fibros) - Sep 15, 2026 - "In this real-world study, ETI was associated with significant improvements in work productivity and activity impairment. These functional gains closely mirror improvements in physical, role, and respiratory domains, highlighting the broader socioeconomic and quality-of-life benefits of ETI beyond traditional clinical endpoints."
Journal • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases
|
|
; Bradley S Quon; Elizabeth Tullis; Felix Ratjen; Grace G Kim; Grace Y Lam; Jonathan Rayment; Lara Bilodeau; Larry C Lands; Taryn Wong; Winnie M Leung
|